Coronary Stents Market Report

Global Coronary Stents Market Size

The global coronary stents market is estimated to grow from USD 11.92 billion in 2024 to USD 21.42 billion in 2033, representing a CAGR of 7.6%.

The Coronary Stents are the global ecosystem of medical devices designed to maintain arterial patency following percutaneous coronary intervention (PCI) in patients with obstructive coronary artery disease. As per the World Health Organization, cardiovascular diseases remain the leading cause of death globally, responsible for an estimated 17.9 million fatalities annually, with ischemic heart disease accounting for nearly 9 million of these. The Global Burden of Disease Study 2023 indicates that over 205 million individuals worldwide suffer from coronary artery disease, a figure that has risen by 29% over the past decade. The increasing prevalence of atherosclerosis, coupled with aging populations and rising rates of diabetes and hypertension, continues to drive clinical reliance on coronary stenting as a life-preserving intervention.

MARKET DRIVERS

Escalating Global Burden of Coronary Artery Disease and Myocardial Infarctions

The rising incidence of coronary artery disease (CAD) is a primary driver of the growth of the Coronary Stents Market. According to the Global Burden of Disease Study 2023, CAD prevalence has surged to 205 million cases globally, with low- and middle-income countries experiencing the steepest increases due to urbanization and lifestyle shifts. As per the American Heart Association, approximately 605,000 new myocardial infarctions occur annually in the United States, with 90% treated via PCI and stent placement.

Advancements in Stent Technology and Favorable Clinical Outcomes

The technological innovation in stent design has significantly improved patient outcomes with clinical confidence and adoption is also enhancing the growth of the Coronary Stents Market. Drug-eluting stents (DES), which release anti-proliferative agents to prevent restenosis, now dominate over 90% of PCI procedures globally, as per the European Society of Cardiology. The 2023 ISAR-REACT 6 trial demonstrated that newer-generation DES reduced target lesion failure by 38% compared to early models, with a 1.2% rate of stent thrombosis at one year.

MARKET RESTRAINTS

High Cost of Advanced Stents and Limited Reimbursement in Emerging Economies

The high price of next-generation stents restricts accessibility in resource-constrained healthcare systems is limiting the growth of the Coronary Stents Market. In South Africa, the Council for Medical Schemes noted that only 40% of medical aid plans fully cover DES, forcing many patients to opt for bare-metal stents or forgo intervention. As per India’s National Health Authority, 68% of PCI procedures in public hospitals use bare-metal stents due to budgetary constraints, despite their higher restenosis risk.

Risk of In-Stent Restenosis and Late Thrombosis with Long-Term Implantation

The risks of in-stent restenosis and late stent thrombosis remain clinically significant is also hindering the growth of the Coronary Stents Market. According to a 2023 meta-analysis published in The Lancet, the incidence of restenosis with first-generation DES was 10–15%, improving to 3–5% with newer models, but still necessitating repeat interventions. Late stent thrombosis, though rare, occurs in 0.6% to 1.2% of patients beyond one year, often leading to acute myocardial infarction or sudden death, as documented by the American College of Cardiology.

MARKET OPPORTUNITIES

Expansion of Minimally Invasive Cardiac Interventions in Emerging Markets

The growing adoption of minimally invasive procedures in developing nations is expected to bolster the growth of the Coronary Stents Market. As per Thailand’s Ministry of Public Health in 2023, a 28% year-on-year increase in PCI procedures by national training programs for interventional cardiologists. These expansions are fueled by government investments in tertiary care infrastructure and partnerships with international medical device firms by creating scalable demand for both standard and premium stent technologies across public and private healthcare networks.

Development of Bioresorbable and Patient-Specific Stents

The emergence of bioresorbable vascular scaffolds (BVS) and patient-tailored stents offers transformative potential in coronary intervention is amplifying the growth of the Coronary Stents Market. The ABSORB III trial extension data, published in 2023, showed that BVS achieved comparable outcomes to DES in non-complex lesions, with 92% vessel healing at 36 months. Companies like Biotronik and Medtronic are advancing magnesium-based resorbable stents with improved radial strength. Additionally, 3D-printed patient-specific stents are being explored in complex anatomies.

MARKET CHALLENGES

Stringent Regulatory Pathways and Lengthy Clinical Validation Requirements

The approval process for coronary stents is highly rigorous, which is requiring extensive preclinical testing and long-term clinical trials to demonstrate safety and efficacy. The U.S. Food and Drug Administration mandates pivotal trials with at least 1,000 patients and follow-up periods of up to five years for novel stent platforms. In the European Union, the Medical Device Regulation (MDR) has intensified scrutiny, requiring real-world performance data and post-market surveillance plans before CE marking. As per the European Association of Percutaneous Cardiovascular Interventions, the average time to market for a new stent has increased from 24 to 38 months since 2021.

Increasing Adoption of Non-Stent Revascularization Therapies and Medical Management

A growing number of patients are being managed with optimal medical therapy (OMT) or alternative revascularization methods by reducing reliance on stenting is hampering the growth of the Coronary Stents Market. In the UK, the National Institute for Health and Care Excellence reported that 35% of stable angina patients now receive OMT as first-line treatment, avoiding stent implantation. Additionally, enhanced external counterpulsation (EECP) and gene therapy trials are emerging as non-invasive alternatives.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The Drug-Eluting Stents (DES) segment was the largest and held a dominant share of the global coronary stents market in 2024 with their superior clinical efficacy in preventing restenosis compared to bare-metal alternatives. According to a 2023 multicenter registry conducted by the American College of Cardiology, DES reduced the rate of target vessel revascularization by 65% within the first year post-procedure compared to bare-metal stents (BMS). The SYNERGY trial extension data confirmed that newer-generation DES, such as those with biodegradable polymer coatings, demonstrated a 2.8% incidence of in-stent restenosis over 24 months, which is significantly lower than the 15–20% historically observed with BMS.

The Bioabsorbable Stents segment is swiftly emerging with an expected CAGR of 8.3% during the forecast period with the technology’s potential to restore natural vessel physiology after dissolution, eliminating long-term risks associated with permanent metallic implants. The 2023 ABSORB IV trial follow-up demonstrated that second-generation bioresorbable scaffolds achieved 91% vessel patency at three years with a 1.4% rate of device-oriented composite events by nearing the performance of modern DES.

By Mode of Delivery Insights

The Balloon-Expandable Stents segment held a dominant share of the coronary stents market in 2024 with their precision in deployment and superior radial strength, making them ideal for treating focal coronary lesions. According to clinical data from the Mayo Clinic, balloon-expandable stents achieve near-complete apposition in 96% of cases, minimizing the risk of malapposition and subsequent thrombosis.

The Self-Expanding Stents segment is projected to grow with an anticipated CAGR of 6.7% from 2025 to 2033 due to their increasing application in complex anatomies and bifurcated vessels where flexibility and dynamic adaptation are essential. Self-expanding stents, typically made from nitinol, are being explored for use in saphenous vein grafts and distal coronary segments prone to movement. A 2023 pilot study at Stanford University showed that self-expanding stents maintained 94% lumen patency in highly mobile coronary segments over 12 months, outperforming rigid platforms.

By Material Insights

The metallic stents segment is leading with the dominant shares of the market owing to rising demand for the launch of innovative products in favor of patient safety. Rapid urbanization and a growing economy are factors anticipated to accelerate the growth rate of this segment. The cobalt chromium segment is expected to have the fastest growth rate in the coming years.

By End-User Insights

The hospitals segment was the largest and held a prominent share of the coronary stents market in 2024 with the infrastructure required for percutaneous coronary interventions, including catheterization labs, specialized cardiac imaging, and multidisciplinary teams. In the United States, the American Hospital Association recorded that 98% of PCI procedures were performed in acute care hospitals, with over 750,000 interventions conducted in 2023.

The Ambulatory Surgical Centers (ASCs) segment is expected to grow with an expected CAGR of 7.2% during the forecast period, with the rising trend of outpatient cardiovascular procedures, cost-efficiency, and advancements in minimally invasive techniques. In the United States, the Centers for Medicare & Medicaid Services expanded reimbursement for low-risk PCI procedures performed in certified ASCs in 2023 by enabling over 15,000 stent placements in such facilities that year. Additionally, the Texas Medical Board reported a 50% increase in ASCs accredited for cardiac interventions between 2021 and 2023.

REGIONAL ANALYSIS

North America was the largest contributor to the global coronary stents market by holding 34.3% of the share in 2024 owing to the high prevalence of cardiovascular disease, advanced interventional cardiology infrastructure, and widespread adoption of next-generation stents. Canada’s adoption of DES has also risen, with provincial health systems increasingly covering bioresorbable stents for select patients. The U.S. Food and Drug Administration’s expedited review pathways for innovative stent technologies have accelerated market entry, while private insurance coverage ensures patient access.

Europe was ranked second with 29.3% of the Coronary Stents Market share in 2024, with the robust public healthcare systems, strong clinical guidelines, and high procedural volumes, as per the European Society of Cardiology. Germany, France, and the United Kingdom are the primary contributors, collectively performing over 500,000 PCIs annually. The Euro Heart Survey 2023 revealed that 91% of PCI procedures in Western Europe utilized drug-eluting stents, with bioresorbable platforms gaining traction in younger patients. Additionally, countries like Sweden and the Netherlands are investing in hybrid operating rooms and digital health integration by enhancing procedural efficiency and long-term patient monitoring.

Asia-Pacific (APAC) coronary stents market growth is lucratively to have prominent opportunities with rapid expansion fueled by rising cardiovascular disease burden and improving healthcare access, as reported by the Asian Pacific Society of Cardiology. China is the largest market in the region, conducting over 1.3 million PCIs in 2023, a 22% increase from 2021, according to the Chinese Society of Cardiology. India’s stent penetration is growing, with over 400,000 procedures performed annually, supported by government price caps on DES to improve affordability. Japan remains a leader in technological adoption, with over 60% of stents used in robotic-assisted or imaging-guided interventions.

Latin America Coronary Stents Market growth is expected to have prominent opportunities during the forecast period. Brazil’s Unified Health System performed over 120,000 PCIs in 2023, with stent use increasing by 15% year-on-year, according to the Brazilian Society of Cardiology. Mexico’s Institute for Health Care Quality reported that 78% of PCI procedures utilized drug-eluting stents, reflecting improved access to advanced care. Argentina has expanded interventional cardiology training, increasing the number of certified labs by 25% since 2020. Public-private partnerships and regional stent manufacturing, such as Brazil’s partnership with Medtronic, are helping bridge gaps in availability and affordability.

Middle East and Africa (MEA) Coronary Stents Market growth is driven by prominent opportunities in the coming years. Saudi Arabia’s Vision 2030 healthcare transformation has led to a 30% increase in PCI procedures since 2020, with the Ministry of Health reporting over 45,000 stent placements in 2023. The UAE has established specialized cardiac centers in Dubai and Abu Dhabi, achieving Western-standard outcomes in stent deployment.

KEY MARKET PLAYERS

Notable companies leading the global coronary stents market profiled in the report are Medtronic plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), Biosensors International Group, Ltd. (Singapore), BIOTRONIK SE & Co. KG (Germany), B Braun Melsungen AG (Germany), TERUMO CORPORATION (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany).

The competition in the coronary stents market is marked by a dynamic interplay between global innovators and regional manufacturers, with differentiation increasingly based on clinical performance, technological sophistication, and post-market support rather than price alone. Multinational corporations such as Medtronic, Abbott, and Terumo dominate through advanced drug-eluting platforms and robust clinical data, while local players in India and China are gaining ground with cost-effective alternatives approved for public procurement. Regulatory harmonization under frameworks like the EU MDR and the FDA’s breakthrough device program favors established firms with strong R&D capabilities. However, the rise of bioresorbable and patient-specific stents is creating new battlegrounds for innovation. Additionally, increasing scrutiny on long-term outcomes and healthcare economics is pushing companies to demonstrate not only safety and efficacy but also value across the patient care continuum.

Top Players in the Coronary Stents Market

Medtronic

Medtronic maintains a prominent presence in the Asia-Pacific coronary stents market through its advanced drug-eluting stent platforms and strategic collaborations with regional healthcare providers. The company’s Resolute Onyx™ DES is widely adopted across Japan, South Korea, and Australia due to its proven efficacy in complex lesions and compliance with local regulatory standards. In 2023, Medtronic expanded its manufacturing footprint in Malaysia to support regional supply resilience and reduce lead times. The company also partnered with India’s Apollo Hospitals to integrate its stents into standardized PCI protocols by enhancing clinical adoption. Additionally, Medtronic launched a physician training initiative in Indonesia in collaboration with the Indonesian College of Cardiology, focusing on optimal stent placement techniques and intravascular imaging. These efforts reinforce its reputation for clinical excellence and long-term engagement with interventional cardiology ecosystems across diverse healthcare settings.

Abbott Laboratories

Abbott has its influence in the Asia-Pacific coronary stents market through the widespread adoption of its XIENCE family of drug-eluting stents, recognized for their durable polymer technology and favorable long-term outcomes. The company has established distribution networks across China, India, and Southeast Asia, ensuring access to both urban tertiary centers and emerging tier-2 hospitals. In 2023, Abbott received regulatory approval in Japan for its next-generation XIENCE SKY™ stent, featuring enhanced deliverability for tortuous anatomy.

Terumo Corporation

Terumo, headquartered in Japan that leverages its regional proximity and deep clinical integration to lead in the Asia-Pacific coronary stents market with its Ultimaster™ drug-eluting stent, which features a biodegradable polymer and fluorine-coated surface for improved endothelial healing. The device has gained rapid acceptance in Japan, South Korea, and India, where it is included in public hospital procurement lists due to cost-effectiveness and strong clinical data. In 2023, Terumo expanded its production capacity at its facility in Aichi, Japan, to meet rising demand from national health programs. The company also collaborated with the Cardiological Society of India to conduct live demonstration procedures showcasing the stent’s performance in bifurcation lesions.

Top Strategies Used by the Key Market Participants

Key players in the coronary stents market are deploying a combination of technological innovation, clinical evidence generation, regional localization, physician education, and strategic partnerships to consolidate their market standing. Companies are investing heavily in next-generation platforms such as bioresorbable scaffolds and ultra-thin strut stents to differentiate their offerings. Real-world clinical studies and registry participation are being leveraged to validate performance and gain regulatory and reimbursement advantages. Localization of manufacturing and supply chains enhances responsiveness and reduces costs in price-sensitive markets. Firms are also expanding training programs for interventional cardiologists to improve procedural outcomes and brand loyalty.

RECENT HAPPENINGS IN THE MARKET

• In February 2023, Medtronic launched a physician training program in Jakarta, Indonesia, in partnership with the Indonesian College of Cardiology, to enhance the adoption of its Resolute Onyx™ drug-eluting stent in complex coronary interventions.
• In May 2023, Abbott received regulatory approval in Japan for its XIENCE SKY™ stent, enabling market access for its next-generation DES with improved deliverability in tortuous coronary anatomy.
• In July 2023, Terumo expanded production capacity at its Aichi, Japan, facility to meet rising demand for the Ultimaster™ stent across Asia-Pacific public health programs and private hospitals.
• In October 2023, Abbott initiated a real-world evidence study in Bangkok, Thailand, in collaboration with the National Health Security Office, to evaluate the long-term performance of XIENCE stents in diabetic patients.
• In March 2024, Medtronic partnered with Apollo Hospitals in India to standardize PCI protocols using its coronary stents, integrating device use into clinical pathways across 70+ hospital network sites.

MARKET SEGMENTATION

This research report on the global coronary stents market has been segmented and sub-segmented based on the type, mode of delivery, material, end-user, and region.

By Type

• Bare Metal Stents
• Drug-Eluting Stents
• Bioabsorbable Stents

By Mode of Delivery

• Balloon-Expandable Stents
• Self-Expanding Stents

By Material

• Metallic Stents
  • Cobalt-Chromium
  • Platinum Chromium
  • Nickel-Titanium
  • Stainless Steel
• Other Stents

By End-User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa